Drugmakers Saw Robust ROI and Lower Development Costs in 2021, Says Analysis Post author:PacConAdmin Post published:January 12, 2022 Post category:Drug Industry Daily It’s been a banner year for the financial side of the pharmaceutical industry. Source: Drug Industry Daily You Might Also Like U.S. Cancer Drug Prices Continue to Rise, Despite Competition March 28, 2022 New Jersey Contract Tester Warned for API Testing Violations May 20, 2020 FDA Oncology Leaders Sketch Out New Trial Designs for Accelerated Approvals September 26, 2022